Protara's $45M placement; Plus, news about Eupraxia and GenSight
05 Apr 2024
Phase 2
Protara Therapeutics raises $45M private placement: The oversubscribed financing transaction is set to close April 10. The proceeds should extend the company’s runway through 2026 and help fund an ongoing Phase 2 trial of TARA-002 in high-risk non-muscle invasive bladder cancer. — Ayisha Sharma
Eupraxia Pharmaceuticals makes Nasdaq debut: The Canadian company, which focuses on developing treatments for inflammatory joint conditions and cancer, is now trading under the ticker $EPRX. Eupraxia is using its so-called Diffusphere technology to enable targeted delivery of active ingredients with extended effect duration and “tunable” PK profiles. — Ayisha Sharma
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.